Afamelanotide · source year
8 selected, source-linked Afamelanotide records carrying a 2023 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
8 selected records.
3 represented types.
8 distinct public records.
Cited chronology
Literature metadata
PubMed lists PMID 28003770 in The application of clinical genetics as Review, Journal Article, with publication-date metadata of 2016-12-12 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Regulatory
DailyMed lists Structured Product Labeling version 7 for the reviewed Afamelanotide label family with a published date of 2023-10-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04525157 at 2026-07-30T19:08:50.172Z. Its registry update date was 2023-09-22, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 6 for the reviewed Afamelanotide label family with a published date of 2023-05-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04962503 at 2026-07-30T19:14:02.188Z. Its registry update date was 2023-04-11, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Regulatory
The Federal Register published notice 2023-03364, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide, Glucagon, Leuprolide and Vosoritide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05368857 at 2026-07-30T19:16:22.169Z. Its registry update date was 2023-02-09, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 5 for the reviewed Afamelanotide label family with a published date of 2023-01-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.